Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Xuemei Liao, Hui Ye & Tianmei Si. (2021) A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities. Neuropsychiatric Disease and Treatment 17, pages 453-469.
Read now
Read now
Rajeev Ayyagari, Darren Thomason, Fan Mu, Michael Philbin & Benjamin Carroll. (2020) Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders. Journal of Medical Economics 23:2, pages 204-212.
Read now
Read now
Wade Marteene, Karl Winckel, Sam Hollingworth, Steve Kisely, Erin Gallagher, Margaret Hahn, Bjørn H Ebdrup, Joseph Firth & Dan Siskind. (2019) Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opinion on Drug Safety 18:12, pages 1149-1160.
Read now
Read now
Ying Liang & Xin Yu. (2017) The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study. Neuropsychiatric Disease and Treatment 13, pages 1163-1173.
Read now
Read now
Rayees Ahmad Wani, Mansoor Ahmad Dar, Rajesh Kumar Chandel, Yasir Hassan Rather, Inaamul Haq, Arshad Hussain & Altaf Ahmad Malla. (2015) Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatric Disease and Treatment 11, pages 685-693.
Read now
Read now
Ann M Mortimer. (2009) Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatric Disease and Treatment 5, pages 267-277.
Read now
Read now
Articles from other publishers (16)
. 2020. Oxford Handbook of Clinical Specialties. Oxford Handbook of Clinical Specialties.
Ambreen K. Ghori, Martha Sajatovic & Rajesh R. Tampi. (2016) A Case of Emergent Restless Legs Syndrome With Lurasidone Therapy. Journal of Clinical Psychopharmacology 36:3, pages 293-294.
Crossref
Crossref
Anja Cerovecki, Richard Musil, Ansgar Klimke, Florian Seemüller, Ekkehard Haen, Rebecca Schennach, Kai-Uwe Kühn, Hans-Peter Volz & Michael Riedel. (2013) Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations. CNS Drugs 27:7, pages 545-572.
Crossref
Crossref
Miguel Gutiérrez Fraile, Jesús J. de la Gándara Martín & Julio Bobes García. (2013) Switching to Ziprasidone in the Clinical Practice Setting: An Open-Label Study. The International Journal of Psychiatry in Medicine 45:2, pages 125-142.
Crossref
Crossref
Miquel Bernardo, Eduard Vieta, Jerónimo Saiz Ruiz, Fernando Rico-Villademoros, Cecilio Álamo & Julio Bobes. (2011) Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. Revista de Psiquiatría y Salud Mental (English Edition) 4:3, pages 150-168.
Crossref
Crossref
Miquel Bernardo, Eduard Vieta, Jerónimo Saiz Ruiz, Fernando Rico-Villademoros, Cecilio Álamo & Julio Bobes. (2011) Recomendaciones para el cambio de antipsicóticos. Posicionamiento de la Sociedad Española de Psiquiatría y Sociedad Española de Psiquiatría Biológica. Revista de Psiquiatría y Salud Mental 4:3, pages 150-168.
Crossref
Crossref
Robert B. Penfold, Kelly J. Kelleher, Wei Wang, Brandon Strange & Kathleen Pajer. (2010) Pediatric Uptake of a Newly Available Antipsychotic Medication. Pediatrics 125:3, pages 475-482.
Crossref
Crossref
Rohan Ganguli, Jaspreet S Brar, Ramy Mahmoud, Sally A Berry & Gahan J Pandina. (2008) Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study. BMC Medicine 6:1.
Crossref
Crossref
Luca Pani, José M Villagrán, Vassilis P Kontaxakis & Köksal Alptekin. (2008) Practical Issues with Amisulpride in the Management of Patients with Schizophrenia. Clinical Drug Investigation 28:8, pages 465-477.
Crossref
Crossref
Michael Linden, Tabea ScheelFranz-Xaver Eich. (2006) Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride. Journal of Psychopharmacology 20:6, pages 815-823.
Crossref
Crossref
Ilkka Larmo, André de Nayer, Elmar Windhager, Irmansyah, Bernhard Lindenbauer, Hans Rittmannsberger, Thomas Platz, A. Martin Jones & Charles Altman. (2005) Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Human Psychopharmacology: Clinical and Experimental 20:8, pages 573-581.
Crossref
Crossref
Howard C Margolese, Guy Chouinard, Theodore T Kolivakis, Linda Beauclair, Robert Miller & Lawrence Annable. (2005) Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics. Part 2: Incidence and Management Strategies in Patients with Schizophrenia. The Canadian Journal of Psychiatry 50:11, pages 703-714.
Crossref
Crossref
Pierre Chue, Emmanuel Stip, Gary Remington & Lili Kopala. (2014) Switching atypical antipsychotics: a review. Acta Neuropsychiatrica 16:6, pages 301-313.
Crossref
Crossref
Kate McKeage & Greg L Plosker. (2004) Amisulpride. CNS Drugs 18:13, pages 933-956.
Crossref
Crossref
Patrice Boyer. (2020) Sense and non-sense of polypharmacy: increasing efficacy, decreasing compliance?. European Psychiatry 18:S2, pages 54s-61s.
Crossref
Crossref
. (2003) Current Awareness in Human Psychopharmacology. Human Psychopharmacology: Clinical and Experimental 18:1, pages 83-88.
Crossref
Crossref